{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:28:58Z","timestamp":1773091738356,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatic cancer (PC) is a major cause of cancer death. In an effort to improve treatment strategies and outcomes, DNA damage repair (DDR) pathways have been introduced as a new target in PC and in other cancers, through the exploitation of synthetic lethality. Furthermore, genes involved in DDR are among the major determinants of cancer susceptibility. In addition to the well-known <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> genes, a plethora of other targets in the same pathways are now emerging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed samples from 60 patients, affected by PC and already tested for <jats:italic>BRCA<\/jats:italic>, using a panel with 24 other cancer susceptibility genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We detected 8 pathogenic or likely pathogenic mutations (13.3% of samples analyzed), 4 of which were found in non-<jats:italic>BRCA<\/jats:italic> genes (2 in <jats:italic>ATM<\/jats:italic>, 1 each in <jats:italic>PALB2<\/jats:italic> and <jats:italic>RAD50<\/jats:italic>). Furthermore, 4 pathogenic or likely pathogenic mutations were found in patients without a personal or familial history of cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggest that genetic testing with a comprehensive gene panel should be perfomed in all patients with PC, in order to allow screening for PC and other gene-related cancers in all at risk family members and to assess patients\u2019 eligibility for emerging therapeutic options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08368-5","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:07:16Z","timestamp":1621984036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Ilario Giovanni","family":"Rapposelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Zampiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Cangini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Ravegnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Valgiusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Calistri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Luca","family":"Frassineti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Falcini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"issue":"6","key":"8368_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8368_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"10039","key":"8368_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(16)00141-0.","journal-title":"Lancet."},{"issue":"19","key":"8368_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"8368_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"5","key":"8368_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell."},{"issue":"25","key":"8368_CR7","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1200\/JCO.18.02050","volume":"37","author":"C Gourley","year":"2019","unstructured":"Gourley C, Balma\u00f1a J, Ledermann JA, Serra V, Dent R, Loibl S, et al. Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019;37(25):2257\u201369. https:\/\/doi.org\/10.1200\/JCO.18.02050.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8368_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cncr.29041","volume":"121","author":"J Mersch","year":"2015","unstructured":"Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2):269\u201375. https:\/\/doi.org\/10.1002\/cncr.29041.","journal-title":"Cancer."},{"issue":"5","key":"8368_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","volume":"43","author":"GM Petersen","year":"2016","unstructured":"Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43(5):548\u201353. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.09.002.","journal-title":"Semin Oncol"},{"key":"8368_CR10","doi-asserted-by":"publisher","unstructured":"Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015:3124\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.7401.","DOI":"10.1200\/JCO.2014.59.7401"},{"issue":"1","key":"8368_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","volume":"585","author":"SMB Nijman","year":"2011","unstructured":"Nijman SMB. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 2011;585(1):1\u20136. https:\/\/doi.org\/10.1016\/j.febslet.2010.11.024.","journal-title":"FEBS Lett"},{"issue":"6","key":"8368_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111(6):1132\u20138. https:\/\/doi.org\/10.1038\/bjc.2014.418.","journal-title":"Br J Cancer"},{"issue":"3","key":"8368_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S, O\u2019Dwyer PJ, Domchek SM, Nathanson KL, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122(3):333\u20139. https:\/\/doi.org\/10.1038\/s41416-019-0582-7.","journal-title":"Br J Cancer"},{"issue":"4","key":"8368_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/nejmoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for germline BRCA -mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327. https:\/\/doi.org\/10.1056\/nejmoa1903387.","journal-title":"N Engl J Med"},{"issue":"15","key":"8368_CR15","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (hrd) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"8368_CR16","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/nejmoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and Olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708. https:\/\/doi.org\/10.1056\/nejmoa1506859.","journal-title":"N Engl J Med"},{"issue":"22","key":"8368_CR17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/nejmoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102. https:\/\/doi.org\/10.1056\/nejmoa1911440.","journal-title":"N Engl J Med"},{"issue":"1","key":"8368_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(19)30684-9.","journal-title":"Lancet Oncol"},{"issue":"11","key":"8368_CR19","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"W Abida","year":"2020","unstructured":"Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor Rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26(11):2487\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0394.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"8368_CR20","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.ccr-20-1301","volume":"26","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, et al. A phase I\/II study of Veliparib (ABT-888) in combination with 5-fluorouracil and Oxaliplatin in patients with metastatic pancreatic cancer. Clin Cancer Res. 2020;26(19):5092\u2013101. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-1301.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8368_CR21","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282\u201391. https:\/\/doi.org\/10.1002\/humu.20880.","journal-title":"Hum Mutat"},{"key":"8368_CR22","unstructured":"BRCA ShareTM. Available online: http:\/\/www.umd.be\/BRCA1\/ (Accessed on 9 Oct 2020)."},{"key":"8368_CR23","unstructured":"Leiden Open Variation Database. Available online: https:\/\/databases.lovd.nl\/shared\/genes (Acessed on 9 Oct 2020)."},{"key":"8368_CR24","unstructured":"BRCA Exchange. Available online: https:\/\/brcaexchange.org\/variants (accessed on 9 Oct 2020)."},{"key":"8368_CR25","unstructured":"ClinVar. Available online: www.ncbi.nlm.nih.gov\/clinvar (Accessed on 9 Oct 2020)."},{"key":"8368_CR26","unstructured":"dbSNP. Available online: www.ncbi.nlm.nih.gov\/projects\/SNP (Accessed on 9 Oct 2020)."},{"key":"8368_CR27","unstructured":"HCI Cancer Susceptibility Genes Prior Probabilities of Pathogenicity. Available online: http:\/\/priors.hci.utah.edu\/PRIORS\/ (Accessed on 9 Oct 2020)."},{"key":"8368_CR28","unstructured":"Varsome. Available online: https:\/\/varsome.com (Accessed on 9 Oct 2020)."},{"issue":"1","key":"8368_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13053-019-0104-x","volume":"17","author":"M Ram\u00edrez-Calvo","year":"2019","unstructured":"Ram\u00edrez-Calvo M, Garc\u00eda-Casado Z, Fern\u00e1ndez-Serra A, De Juan I, Palanca S, Oltra S, et al. Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the hereditary cancer Programme of the Valencia community (FamCan-NGS). Hered Cancer Clin Pract. 2019;17(1):3. https:\/\/doi.org\/10.1186\/s13053-019-0104-x.","journal-title":"Hered Cancer Clin Pract"},{"issue":"5","key":"8368_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"1","key":"8368_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/gim.2017.85","volume":"20","author":"KG Chaffee","year":"2018","unstructured":"Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018;20(1):119\u201327. https:\/\/doi.org\/10.1038\/gim.2017.85.","journal-title":"Genet Med"},{"issue":"7","key":"8368_CR32","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674\u201385. https:\/\/doi.org\/10.1200\/JCO.19.01907.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8368_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","volume":"2","author":"NJ Roberts","year":"2012","unstructured":"Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41\u20136. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0194.","journal-title":"Cancer Discov"},{"issue":"2","key":"8368_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","volume":"6","author":"NJ Roberts","year":"2016","unstructured":"Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6(2):166\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0402.","journal-title":"Cancer Discov"},{"issue":"2","key":"8368_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10577-008-9018-6","volume":"17","author":"E Kinoshita","year":"2009","unstructured":"Kinoshita E, Van Der Linden E, Sanchez H, Wyman C. RAD50, an SMC family member with multiple roles in DNA break repair: how does ATP affect function? Chromosom Res. 2009;17(2):277\u201388. https:\/\/doi.org\/10.1007\/s10577-008-9018-6.","journal-title":"Chromosom Res"},{"issue":"1","key":"8368_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","volume":"21","author":"MB Yurgelun","year":"2019","unstructured":"Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019;21(1):213\u201323. https:\/\/doi.org\/10.1038\/s41436-018-0009-5.","journal-title":"Genet Med"},{"issue":"4","key":"8368_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/0008-5472.CAN-07-6272","volume":"68","author":"X Wang","year":"2008","unstructured":"Wang X, Szabo C, Qian C, Amadio PG, Thibodeau SN, Cerhan JR, et al. Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res. 2008;68(4):971\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6272.","journal-title":"Cancer Res"},{"key":"8368_CR38","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.3892\/ol.2020.11491","volume":"19","author":"K Jia","year":"2020","unstructured":"Jia K, Zhao X, Dang X. Mass spectrometry-based iTRAQ analysis of serum markers in patients with pancreatic cancer. Oncol Lett. 2020;19:4106\u201314. https:\/\/doi.org\/10.3892\/ol.2020.11491.","journal-title":"Oncol Lett"},{"issue":"10","key":"8368_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10101447","volume":"10","author":"Z Ming","year":"2020","unstructured":"Ming Z, Lim SY, Rizos H. Genetic alterations in the ink4a\/arf locus: effects on melanoma development and progression. Biomolecules. 2020;10(10):1\u201317. https:\/\/doi.org\/10.3390\/biom10101447.","journal-title":"Biomolecules."},{"issue":"13","key":"8368_CR40","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26(13):3239\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0418.","journal-title":"Clin Cancer Res"},{"key":"8368_CR41","doi-asserted-by":"publisher","unstructured":"Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Sim\u00f5es C, Wiesm\u00fcller L, et al. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70(3):606-17. https:\/\/doi.org\/10.1136\/gutjnl-2019-319984.","DOI":"10.1136\/gutjnl-2019-319984"},{"issue":"7540","key":"8368_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501. https:\/\/doi.org\/10.1038\/nature14169.","journal-title":"Nature."},{"issue":"7766","key":"8368_CR43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","volume":"571","author":"P Jonsson","year":"2019","unstructured":"Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571(7766):576\u20139. https:\/\/doi.org\/10.1038\/s41586-019-1382-1.","journal-title":"Nature."},{"issue":"13","key":"8368_CR44","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/ PALB2 mutation. J Clin Oncol. 2020;38(13):1378\u201388. https:\/\/doi.org\/10.1200\/JCO.19.02931.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8368_CR45","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol. 2020;21(4):508\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(20)30074-7.","journal-title":"Lancet Oncol"},{"key":"8368_CR46","unstructured":"National Comprehensive Cancer Network. Pancreatic Adenocarcinoma, Version 1.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed on 20 Oct 2020."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08368-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:11:04Z","timestamp":1621984264000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08368-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8368"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08368-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board (Ethics Committee IRST IRCCS-AVR, 2207\/2012) and conducted in accordance with the Declaration of Helsinki. Patients have signed informed consent before analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"611"}}